UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

European journal of cancer (1990), 2011, Vol.47, p.S98-S99

2011

Volltextzugriff (PDF)

Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study

Annals of oncology, 2018-10, Vol.29, p.viii430-viii430

2018

Volltextzugriff (PDF)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Volltextzugriff (PDF)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Volltextzugriff (PDF)

881PDIMPLEMENTATION OF ROUTINE BRCA GENE TESTING OF OVARIAN CANCER (OC) PATIENTS AT ROYAL MARSDEN HOSPITAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv307-iv307

2014

Volltextzugriff (PDF)

902POVARIAN CARCINOSARCOMA MANAGEMENT: A RETROSPECTIVE ANALYSIS OF THE ROYAL MARSDEN EXPERIENCE

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv314-iv314

2014

Volltextzugriff (PDF)

Implementation of Routine Brca Gene Testing of Ovarian Cancer (Oc) Patients at Royal Marsden Hospital

Annals of oncology, 2014-09, Vol.25, p.iv307

2014

Volltextzugriff (PDF)

Ovarian Carcinosarcoma Management: a Retrospective Analysis of the Royal Marsden Experience

Annals of oncology, 2014-09, Vol.25, p.iv314

2014

Volltextzugriff (PDF)

Clinical Outcomes of Recurrent Ovarian Granulosa Cell Tumours Treated with Letrozole: a 10-Year Retrospective Case-Series of the Royal Marsden Hospital

Annals of oncology, 2014-09, Vol.25, p.iv305

2014

Volltextzugriff (PDF)

877PDCLINICAL OUTCOMES OF RECURRENT OVARIAN GRANULOSA CELL TUMOURS TREATED WITH LETROZOLE: A 10-YEAR RETROSPECTIVE CASE-SERIES OF THE ROYAL MARSDEN HOSPITAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv305-iv306

2014

Volltextzugriff (PDF)

Vegetative Compatibility and Pathogenicity of Verticillium dahliae Isolates from the Aegean Region of Turkey

Phytoparasitica, 2007, Vol.35 (3), p.222-231

Gore, M.E

2007

Volltextzugriff (PDF)

Second primary melanomas on treatment with vemurafenib: reply from the authors: Correspondence

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.888-889

2013

Volltextzugriff (PDF)

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

European journal of cancer supplements, 2009, Vol.7 (3), p.21-21

2009

Volltextzugriff (PDF)

Interim Results of a Phase II Study of Sunitinib and Low Dose Metronomic Cyclophosphamide in Advanced Renal Cell Cancer

Annals of oncology, 2012-09, Vol.23, p.ix273-ix274

2012

Volltextzugriff (PDF)

972PD - Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Annals of oncology, 2012-09, Vol.23, p.ix320-ix320

2012

Volltextzugriff (PDF)

Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Annals of oncology, 2012-09, Vol.23, p.ix320

2012

Volltextzugriff (PDF)

A Phase 1, Dose Escalation Study of Paclitaxel with Gsk1120212 (Trametinib) for the Treatment of Advanced Melanoma

Annals of oncology, 2014-09, Vol.25, p.iv379

2014

Volltextzugriff (PDF)

1094PDA PHASE 1, DOSE ESCALATION STUDY OF PACLITAXEL WITH GSK1120212 (TRAMETINIB) FOR THE TREATMENT OF ADVANCED MELANOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv379-iv379

2014

Volltextzugriff (PDF)

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities: Cutaneous adverse events with vemurafenib: practical advice

British journal of dermatology (1951), 2012-11, Vol.167 (5), p.987-994

2012

Volltextzugriff (PDF)

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Annals of oncology, 2012-09, Vol.23, p.ix262

2012

Volltextzugriff (PDF)

Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (MRCC) – Final Results

Annals of oncology, 2012-09, Vol.23, p.ix271

2012

Volltextzugriff (PDF)

Bevacizumab (BEV) + Low-Dose Interferon-α2A (IFN) for First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC): Final Safety and Efficacy Data from the Prospective Bevlin Study

Annals of oncology, 2012-09, Vol.23, p.ix267

2012

Volltextzugriff (PDF)

Caelyx

European journal of cancer (1990), 2001-12, Vol.37, p.8-14

2001

Volltextzugriff (PDF)

BLUE MOLD EPIDEMICS CAUSED BY PERONOSPORA TABACINA ON TOBACCO IN THE AEGEAN REGION OF TURKEY

Journal of plant pathology, 2010-12, Vol.92 (4), p.S119-S119

2010

Volltextzugriff (PDF)

Geographical and seasonal influences on the distribution of fungal endophytes in Laurus nobilis

Forest pathology = Journal de pathologie forestière = Zeitschrift für Forstpathologie, 2007-08, Vol.37 (4), p.281-288

2007

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(49)
Dissertationen
(1)

Sprache

Englisch
(49)
Afrikaans
(1)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

881PDIMPLEMENTATION OF ROUTINE BRCA GENE TESTING OF OVARIAN CANCER (OC) PATIENTS AT ROYAL MARSDEN HOSPITAL

902POVARIAN CARCINOSARCOMA MANAGEMENT: A RETROSPECTIVE ANALYSIS OF THE ROYAL MARSDEN EXPERIENCE

Implementation of Routine Brca Gene Testing of Ovarian Cancer (Oc) Patients at Royal Marsden Hospital

Ovarian Carcinosarcoma Management: a Retrospective Analysis of the Royal Marsden Experience

Clinical Outcomes of Recurrent Ovarian Granulosa Cell Tumours Treated with Letrozole: a 10-Year Retrospective Case-Series of the Royal Marsden Hospital

877PDCLINICAL OUTCOMES OF RECURRENT OVARIAN GRANULOSA CELL TUMOURS TREATED WITH LETROZOLE: A 10-YEAR RETROSPECTIVE CASE-SERIES OF THE ROYAL MARSDEN HOSPITAL

Vegetative Compatibility and Pathogenicity of Verticillium dahliae Isolates from the Aegean Region of Turkey

Second primary melanomas on treatment with vemurafenib: reply from the authors: Correspondence

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

Interim Results of a Phase II Study of Sunitinib and Low Dose Metronomic Cyclophosphamide in Advanced Renal Cell Cancer

972PD - Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

A Phase 1, Dose Escalation Study of Paclitaxel with Gsk1120212 (Trametinib) for the Treatment of Advanced Melanoma

1094PDA PHASE 1, DOSE ESCALATION STUDY OF PACLITAXEL WITH GSK1120212 (TRAMETINIB) FOR THE TREATMENT OF ADVANCED MELANOMA

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities: Cutaneous adverse events with vemurafenib: practical advice

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (MRCC) – Final Results

Bevacizumab (BEV) + Low-Dose Interferon-α2A (IFN) for First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC): Final Safety and Efficacy Data from the Prospective Bevlin Study

Caelyx

BLUE MOLD EPIDEMICS CAUSED BY PERONOSPORA TABACINA ON TOBACCO IN THE AEGEAN REGION OF TURKEY

Geographical and seasonal influences on the distribution of fungal endophytes in Laurus nobilis

Aktive Filter

Suchergebnisse filtern